MARKET

NVUS

NVUS

Novus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4839
-0.0166
-3.32%
After Hours: 0.4800 -0.0039 -0.81% 19:24 07/10 EDT
OPEN
0.4686
PREV CLOSE
0.5005
HIGH
0.4897
LOW
0.4605
VOLUME
494.23K
TURNOVER
--
52 WEEK HIGH
1.450
52 WEEK LOW
0.2500
MARKET CAP
7.78M
P/E (TTM)
-0.3549
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NVUS stock price target is 1.283 with a high estimate of 2.000 and a low estimate of 0.6000.

EPS

NVUS News

More
The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage
The biotech space saw a flurry of activity last week, with coronavirus-related news, conference presentations and IPOs.
Benzinga · 06/07 17:43
50 Stocks Moving In Tuesday's Mid-Day Session
Gainers Tenax Therapeutics Inc (NASDAQ: TENX) shares climbed 42.3% to $2.07 after the company reported results from its Phase 2 trial of Levosimendan. The trial demonstrated a significant reduction in right atrial and pulmonary capillary wedge pressures.
Benzinga · 06/02 16:21
Why Novus Therapeutics Is Trading Lower Today
Novus Therapeutics (NASDAQ: NVUS) shares are trading lower on Tuesday. Ladenburg Thalmann downgraded the stock from Buy to Neutral and announced a price target of 60 cents per share.
Benzinga · 06/02 15:48
Ladenburg Thalmann Downgrades Novus Therapeutics to Neutral, Announces $0.6 Price Target
Ladenburg Thalmann downgrades Novus Therapeutics (NASDAQ:NVUS) from Buy to Neutral and announces $0.6 price target.
Benzinga · 06/02 11:54
Novus Therapeutics down big on failed ear infection study
Nano cap Novus Therapeutics (NVUS -47.2%) craters on a 13x surge in volume in reaction to unsuccessful results from a Phase 2a clinical trial evaluating in
seekingalpha · 06/01 19:44
Novus Therapeutics stock loses nearly half its value after disappointing drug trial results
Shares of Novus Therapeutics Inc. lost nearly half their value in active trading Monday, after the specialty drug maker announced disappointing trial results of its ear infection treatment. Trading volume spiked to 5.3 million shares, well above the full-day
MarketWatch · 06/01 13:50
Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media
Business Wire · 06/01 13:30
Novus Therapeutics Reports Engaged Financial Advisors To Explore Strategic Options
Benzinga · 06/01 12:50

Industry

Pharmaceuticals
-0.31%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About NVUS

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.
More

Webull offers kinds of Novus Therapeutics Inc stock information, including NASDAQ:NVUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVUS stock methods without spending real money on the virtual paper trading platform.